Epo - erythropoietin Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 24335

Summary

Predicted to enable cytokine activity; erythropoietin receptor binding activity; and protein kinase activator activity. Involved in several processes, including positive regulation of ERK1 and ERK2 cascade; positive regulation of activated T cell proliferation; and response to dexamethasone. Located in cell body and extracellular space. Used to study retinal detachment and visual epilepsy. Biomarker of cholangiocarcinoma; eye disease (multiple); transient cerebral ischemia; and vascular dementia. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); diabetic angiopathy; familial erythrocytosis 5; ischemia (multiple); and neurodegenerative disease (multiple). Orthologous to human EPO (erythropoietin). [provided by Alliance of Genome Resources, Apr 2022]

Epo Products (1)

mRNA Protein Name
NM_017001.2 NP_058697.1 erythropoietin precursor

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
involved in acute-phase response IEP
IEP: Inferred from expression pattern
19840250 RGD
involved in positive regulation of ERK1 and ERK2 cascade IMP
IMP: Inferred from mutant phenotype
21749867 RGD
involved in positive regulation of activated T cell proliferation IDA
IDA: Inferred from direct assay
21649646 RGD
involved in positive regulation of cell population proliferation IMP
IMP: Inferred from mutant phenotype
21749867 RGD
involved in positive regulation of neuron differentiation IDA
IDA: Inferred from direct assay
12876482 RGD
involved in positive regulation of neuron projection development IDA
IDA: Inferred from direct assay
22469063 RGD
involved in response to axon injury IEP
IEP: Inferred from expression pattern
15470751 RGD
involved in response to dexamethasone IEP
IEP: Inferred from expression pattern
21540288 RGD
involved in response to electrical stimulus IEP
IEP: Inferred from expression pattern
19185286 RGD
involved in response to estrogen IEP
IEP: Inferred from expression pattern
15784734 RGD
involved in response to hyperoxia IEP
IEP: Inferred from expression pattern
19768476 RGD
involved in response to hypoxia IEP
IEP: Inferred from expression pattern
19497871 RGD
involved in response to interleukin-1 IEP
IEP: Inferred from expression pattern
9321887 RGD
involved in response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
9321887 RGD
involved in response to nutrient IEP
IEP: Inferred from expression pattern
19136608 RGD
involved in response to salt stress IEP
IEP: Inferred from expression pattern
16815869 RGD
involved in response to testosterone IEP
IEP: Inferred from expression pattern
15778925 RGD
involved in response to vitamin A IEP
IEP: Inferred from expression pattern
9027729 RGD
Cellular Component GO Annotation Evidence References Source
located in cell body IDA
IDA: Inferred from direct assay
17554621 RGD
located in extracellular space IDA
IDA: Inferred from direct assay
15470751 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

erythropoietin

Recombinant Epo Proteins

Cat. No. Product Name Accession Purity
HY-P73040 Erythropoietin Protein, Rat (sf9, His) P29676-1 (A27-R192) ≥ 90%, as determined by reducing SDS-PAGE.

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Phase
HY-12654 Molidustat Inhibitor 99.70% Phase 3
HY-17029 Epothilone B 99.91% Phase 3
HY-P0168A Cibinetide acetate Agonist / Phase 2
HY-163839 DS-1093a Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (25)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-145405 C12-200 99.91% Unkown
HY-P0168 Cibinetide Agonist 99.86% Unkown
HY-112144 TP0463518 Inhibitor 99.25% Unkown
HY-13503 Epothilone A 99.81% Unkown
HY-W040203 Decyl β-D-maltopyranoside 99.94% Unkown
HY-112624K Dextran T5 (MW 5,000) / Unkown
HY-W062700 STS-E412 Activator 99.72% Unkown
HY-141625 TRC160334 Inhibitor 98.22% Unkown
HY-141625A TRC160334 sodium Inhibitor / Unkown
HY-155009 PHD2-IN-1 Inhibitor / Unkown
HY-156526 PHD-IN-1 Inhibitor / Unkown
HY-161660 DS44470011 Inhibitor / Unkown
HY-162438 PHD2-IN-2 Inhibitor / Unkown
HY-177271 PHD2-IN-6 Inhibitor / Unkown
HY-179647 ZG-2686 Agonist / Unkown
HY-183583 HIF-2α-IN-18 Inhibitor / Unkown
HY-RS04446 EPO Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS04459 EPX Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS14538 TIMP1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W747868 Molidustat sodium Inhibitor / Unkown
HY-123939 JAK1/3-IN-1 Inhibitor / Unkown
HY-172335 C9-200 / Unkown
HY-174495 Human EPO mRNA / Unkown
HY-RS16566 Epo Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22999 Epo Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991881 KY1070 / Unkown
HY-108864 Epoetin alfa Agonist / Unkown
HY-P991976 Anti-EPO Antibody Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Epo NCBI NCBI:2056